These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 16476008

  • 1. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
    Akhiani AA, Stensson A, Schön K, Lycke N.
    Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008
    [Abstract] [Full Text] [Related]

  • 2. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
    Nyström-Asklin J, Adamsson J, Harandi AM.
    Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617
    [Abstract] [Full Text] [Related]

  • 3. Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection.
    Shi T, Liu WZ, Gao F, Shi GY, Xiao SD.
    Helicobacter; 2005 Feb; 10(1):71-9. PubMed ID: 15691317
    [Abstract] [Full Text] [Related]

  • 4. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
    Andersen CS, Dietrich J, Agger EM, Lycke NY, Lövgren K, Andersen P.
    Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
    [Abstract] [Full Text] [Related]

  • 5. Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity.
    Nedrud JG, Bagheri N, Schön K, Xin W, Bergroth H, Eliasson DG, Lycke NY.
    PLoS One; 2013 Jan; 8(12):e83321. PubMed ID: 24391754
    [Abstract] [Full Text] [Related]

  • 6. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
    De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W.
    Vaccine; 2006 Jan 30; 24(5):544-51. PubMed ID: 16169634
    [Abstract] [Full Text] [Related]

  • 7. Oral vaccination against Helicobacter pylori with recombinant cholera toxin B-subunit.
    Kubota E, Joh T, Tanida S, Sasaki M, Kataoka H, Watanabe K, Itoh K, Oshima T, Ogasawara N, Togawa S, Wada T, Yamada T, Mori Y, Fujita F, Shimura T, Ohara H, Isaka M, Yasuda Y, Itoh M.
    Helicobacter; 2005 Aug 30; 10(4):345-52. PubMed ID: 16104951
    [Abstract] [Full Text] [Related]

  • 8. Local recall responses in the stomach involving reduced regulation and expanded help mediate vaccine-induced protection against Helicobacter pylori in mice.
    Becher D, Deutscher ME, Simpfendorfer KR, Wijburg OL, Pederson JS, Lew AM, Strugnell RA, Walduck AK.
    Eur J Immunol; 2010 Oct 30; 40(10):2778-90. PubMed ID: 21038469
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of a new tumor necrosis factor-alpha-inducing membrane protein of Helicobacter pylori as a prophylactic vaccine antigen.
    Inoue K, Shiota S, Yamada K, Gotoh K, Suganuma M, Fujioka T, Ahmed K, Iha H, Nishizono A.
    Helicobacter; 2009 Oct 30; 14(5):135-43. PubMed ID: 19751439
    [Abstract] [Full Text] [Related]

  • 10. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
    Agren LC, Ekman L, Löwenadler B, Lycke NY.
    J Immunol; 1997 Apr 15; 158(8):3936-46. PubMed ID: 9103464
    [Abstract] [Full Text] [Related]

  • 11. Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori.
    Hatzifoti C, Roussel Y, Harris AG, Wren BW, Morrow JW, Bajaj-Elliott M.
    Helicobacter; 2006 Apr 15; 11(2):113-22. PubMed ID: 16579841
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background.
    Sutton P, Doidge C, Pinczower G, Wilson J, Harbour S, Swierczak A, Lee A.
    FEMS Immunol Med Microbiol; 2007 Jul 15; 50(2):213-9. PubMed ID: 17567282
    [Abstract] [Full Text] [Related]

  • 13. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
    Eliasson DG, Helgeby A, Schön K, Nygren C, El-Bakkouri K, Fiers W, Saelens X, Lövgren KB, Nyström I, Lycke NY.
    Vaccine; 2011 May 23; 29(23):3951-61. PubMed ID: 21481325
    [Abstract] [Full Text] [Related]

  • 14. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
    Agren LC, Ekman L, Löwenadler B, Nedrud JG, Lycke NY.
    J Immunol; 1999 Feb 15; 162(4):2432-40. PubMed ID: 9973526
    [Abstract] [Full Text] [Related]

  • 15. Transcutaneous immunization with novel lipid-based adjuvants induces protection against gastric Helicobacter pylori infection.
    Hickey DK, Aldwell FE, Tan ZY, Bao S, Beagley KW.
    Vaccine; 2009 Nov 23; 27(50):6983-90. PubMed ID: 19800441
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori.
    Skene CD, Doidge C, Sutton P.
    Vaccine; 2008 Jul 23; 26(31):3880-4. PubMed ID: 18547687
    [Abstract] [Full Text] [Related]

  • 17. Oral immunization with HpaA affords therapeutic protective immunity against H. pylori that is reflected by specific mucosal immune responses.
    Nyström J, Svennerholm AM.
    Vaccine; 2007 Mar 30; 25(14):2591-8. PubMed ID: 17239498
    [Abstract] [Full Text] [Related]

  • 18. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.
    Fang Y, Larsson L, Mattsson J, Lycke N, Xiang Z.
    J Immunol; 2010 Sep 01; 185(5):2935-41. PubMed ID: 20675596
    [Abstract] [Full Text] [Related]

  • 19. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N.
    Vaccine; 2008 Feb 26; 26(9):1243-52. PubMed ID: 18243429
    [Abstract] [Full Text] [Related]

  • 20. [Cellular immunity induced by H.pylori vaccine with chitosan as adjuvant].
    Gong YF, Xie Y, Zhou NJ, Chen J, Zhou XJ, Lu NH, Wang CW.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Jul 26; 23(7):595-9. PubMed ID: 17618575
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.